Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer
This study is ongoing, but not recruiting participants.
Study NCT00002734 Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999 Last Updated: May 30, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ovarian Cancer
Peritoneal Cavity Cancer
Additional conditions recognized in this trial
Ovarian Neoplasms
Peritoneal Neoplasms
More general conditions related to this trial
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Interventions listed in this trial
recombinant interferon alfa
chemotherapy
paclitaxel
topotecan hydrochloride
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Interferon Alfa-2a
Interferon Type I, Recombinant
Interferon-alpha
Interferons
Topotecan
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
University of Alabama at Birmingham
National Cancer Institute (NCI)
Back to top of Main Content
